Rekombinanter CD19 (Inebilizumab Biosimilar) Antikörper
Reaktivität: Human
ELISA, FACS, SPR, Func, BLI
Wirt: Human
Monoclonal
unconjugated
Recombinant Antibody
-
- Target Alle CD19 (Inebilizumab Biosimilar) Produkte
- CD19 (Inebilizumab Biosimilar)
- Antikörpertyp
- Recombinant Antibody
- Reaktivität
- Human
-
Wirt
-
Human
- Expressionssystem
- CHO Cells
-
Klonalität
- Monoklonal
-
Konjugat
- Dieser CD19 (Inebilizumab Biosimilar) Antikörper ist unkonjugiert
- Applikation
- ELISA, Flow Cytometry (FACS), Surface Plasmon Resonance (SPR), Functional Studies (Func), Bio-Layer Interferometry (BLI)
- Verwendungszweck
- Anti-CD19 Reference Antibody (inebilizumab)
- Produktmerkmale
- Anti-CD19 Reference Antibody (inebilizumab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 147.42 kDa.
- Reinheit
- >95 %
- Isotyp
- IgG1
-
-
- Applikationshinweise
- Optimal working dilution should be determined by the investigator.
- Kommentare
-
Conditions: B-cell malignancies Chronic Lymphocytic Leukemia Multiple Myeloma Neuromyelitis optica spectrum disorder Scleroderma
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Konzentration
- 1 mg/mL
- Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
- Lagerung
- 4 °C,-80 °C
- Informationen zur Lagerung
- +4°C,-80°C
-
- Target
- CD19 (Inebilizumab Biosimilar)
- Abstract
- CD19 (Inebilizumab Biosimilar) Produkte
- Substanzklasse
- Biosimilar
- Molekulargewicht
- 147.42 kDa
- UniProt
- P15391
-
Sie sind hier:
